<DOC>
	<DOCNO>NCT02519270</DOCNO>
	<brief_summary>A Phase 1 , Open-Label , Dose-Escalation Study Evaluate Safety , Tolerability , Pharmacokinetics Multiple Intravenous Doses IGN002 Administered Weekly Subjects Refractory Non-Hodgkin Lymphoma ( NHL )</brief_summary>
	<brief_title>Phase 1 , Dose-Escalation Study IGN002 NHL Subjects</brief_title>
	<detailed_description>This open-label , non-randomized , first-in-human Phase 1 study involve two stage : In Dose-Escalation Stage , ascend dose cohort treat 2 period maximum tolerate dose identify . In Period 1 , subject receive 2 dos IGN002 administer weekly . In Period 2 , subject receive 24 additional dos IGN002 administer weekly three 8-week cycle . Subjects progress follow treatment period follow another 6 month . In Expansion Stage , subject receive 24 dos IGN002 identify maximum tolerated dose administer weekly three 8-week cycle . Subjects progress follow treatment period follow another 6 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Documented history immunohistochemistry ( IHC ) confirm CD20positive ( subsequent history CD20negativity ) Bcell , NHL , include diffuse large B cell ( DLBCL ) , mantle cell , marginal zone , lymphoplasmacytic , follicular , transform follicular , primary mediastinal B cell lymphoma Refractory disease , fail available therapy Measurable disease Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy &gt; 3 month Adequate organ function Treatment approve investigational chemotherapy drug within 28 day Day 1 Treatment approve investigational antiCD20 drug within 28 day Day 1 Treatment approve investigational biologic drug target CD20 within 90 day Day 1 Radiation therapy within 4 week Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>